8-K: Tonix Pharmaceuticals Unveils Promising Preclinical Data for Mpox and Smallpox Vaccine Candidate TNX-801

Tonix Pharmaceuticals announced new preclinical findings for its TNX-801 vaccine candidate, demonstrating durable immunity and high attenuation, alongside a strategic shift to subcutaneous administration.

Summary

• Tonix Pharmaceuticals Holding Corp. presented new preclinical findings on its TNX-801 (recombinant horsepox, live virus vaccine) candidate at the Vaccine Congress 2025.
• TNX-801 demonstrated durable immunity while remaining highly attenuated, differentiating it from earlier orthopox vaccines.
• In primary human dermal cells, TNX-801 replicates 27 to 119-fold less than licensed vaccinia strains.
• In interferon receptor knockout mice, TNX-801 is up to 100,000-fold less virulent than legacy vaccines.
• A single dose of TNX-801 produced strong binding and neutralizing antibody responses across multiple animal models, including immunocompromised animals.
• All vaccinated cynomolgus macaques survived lethal Clade I mpox challenge without lesions.
• Rabbit models remained fully protected for fourteen months after a single dose.
• Subcutaneous administration of TNX-801 was found to provide equivalent protection to percutaneous administration, leading the company to prioritize s.c. development due to potential benefits like decreased administration-site bacterial superinfection, scarring, and inadvertent transfer.
• The company believes TNX-801 has the potential to become a critical tool for containing mpox and preparedness against the deliberate reintroduction of smallpox.
• Tonix also highlighted its TNX-102 SL product candidate for fibromyalgia, which has a PDUFA goal date of August 15, 2025, for a marketing authorization decision.

Sentiment

Score: 8

Explanation: The document presents strong positive preclinical data for a key vaccine candidate (TNX-801) addressing significant public health concerns, coupled with a strategic advancement in administration method. Additionally, a near-term PDUFA date for another pipeline asset (TNX-102 SL) adds to the positive outlook, despite the inherent risks of drug development.

Positives

• TNX-801 demonstrated durable immunity and high attenuation, replicating 27 to 119-fold less than licensed vaccinia strains and being up to 100,000-fold less virulent than legacy vaccines.
• A single dose of TNX-801 provided robust immunogenicity and 100% protection against lesions and lethal challenge in animal models (mice, rabbits, hamsters, cynomolgus macaques).
• Rabbit models showed sustained protection for 14 months, indicating durable efficacy.
• The finding that subcutaneous administration provides equivalent protection to percutaneous administration offers a potentially safer and more patient-friendly delivery method, reducing risks of superinfection, scarring, and inadvertent transfer.
• TNX-801 is positioned as a critical tool for mpox containment and smallpox preparedness, addressing ongoing public health concerns.
• TNX-102 SL, another key pipeline candidate, has a PDUFA goal date of August 15, 2025, for fibromyalgia, indicating potential near-term market authorization.
• The company has a contract with the U.S. DoD's Defense Threat Reduction Agency (DTRA) for TNX-4200, valued at up to $34 million over five years.

Risks

• Failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• Failure to successfully market any products.
• Risks related to the timing and progress of clinical development of product candidates.
• Need for additional financing.
• Uncertainties of patent protection and litigation.
• Uncertainties of government or third-party payor reimbursement.
• Limited research and development efforts and dependence upon third parties.
• Substantial competition in the pharmaceutical industry.
• Significant inherent risks in the development, regulatory approval, and commercialization of new pharmaceutical products.

Future Outlook

The company plans to advance TNX-801 into clinical evaluation via subcutaneous delivery, collaborating with public-health partners worldwide. A decision on marketing authorization for TNX-102 SL for fibromyalgia is expected by August 15, 2025. The company continues to develop TNX-1500 for organ transplant rejection, autoimmunity, and cancer, and TNX-4200 as a broad-spectrum antiviral agent.

Management Comments

• "The data show that TNX-801 can deliver durable immunity while remaining highly attenuated, a balance that sets it apart from earlier orthopox vaccines." Seth Lederman, MD, Chief Executive Officer.
• "The novel finding that subcutaneous (s.c.) administration of TNX-801 provides equivalent protection to percutaneous administration, is leading us to develop the s.c. product first." Seth Lederman, MD, Chief Executive Officer.
• "We believe TNX-801 has the potential to become a critical tool for containing mpox and preparedness against the malicious reintroduction of smallpox." Seth Lederman, MD, Chief Executive Officer.
• "Our data show that TNX-801 delivers durable immunity without safety concerns of live virus vaccines." Sina Bavari, PhD, Executive Vice President, Infectious Disease Research and Development.
• "TNX-801 dissociates immune protection from some of the side-effects associated with traditional vaccinia-based vaccines and potentially offers a unique risk-benefit profile for mpox and smallpox prevention." Sina Bavari, PhD, Executive Vice President, Infectious Disease Research and Development.
• "We are excited to advance this program toward clinical evaluation in collaboration with public-health partners worldwide." Sina Bavari, PhD, Executive Vice President, Infectious Disease Research and Development.

Industry Context

The announcement positions TNX-801 as a potentially significant advancement in the field of orthopoxvirus vaccines, particularly for mpox and smallpox, which the World Health Organization and Centers for Disease Control and Prevention continue to classify as ongoing public-health concerns. The development of a single-dose, highly attenuated vaccine with durable immunity and a safer administration route could streamline outbreak responses and offer a unique risk-benefit profile compared to existing options.

Comparison to Industry Standards

• TNX-801 replicates 27 to 119-fold less than licensed vaccinia strains (e.g., VACV-Lister, VACV-New York City Board of Health) in primary human dermal cells, indicating superior attenuation.
• TNX-801 is up to 100,000-fold less virulent than legacy vaccines (e.g., VACV-Western Reserve, VACV-International Health Department, VACV-Lister, VACV-New York City Board of Health) in interferon receptor knockout mice, suggesting a significantly improved safety profile.
• Unlike some traditional vaccinia-based vaccines, TNX-801 aims to dissociate immune protection from common side-effects, potentially offering a unique risk-benefit profile.
• The finding that subcutaneous administration of TNX-801 provides equivalent protection to percutaneous administration offers a potential advantage over traditional methods, which can lead to administration-site bacterial superinfection, scarring, or inadvertent transfer to other body sites by itching.
• The company's NHP immunogenicity study design included rVACV (plaque pick from ACAM2000, an approved vaccine) as a comparator, indicating a benchmark against an established industry standard.

Stakeholder Impact

• Shareholders: Positive preclinical data and a near-term regulatory milestone could enhance investor confidence and potentially influence share price positively.
• Patients/Public Health: The development of TNX-801 offers the potential for a safer and more effective vaccine against mpox and smallpox, addressing critical public health needs.
• Employees: Continued progress in the development pipeline supports the company's growth and stability, potentially benefiting employees.
• Regulatory Authorities: The company's advancements in vaccine development and engagement with the FDA for TNX-102 SL demonstrate active participation in addressing public health and regulatory requirements.

Next Steps

• Advance TNX-801 into clinical evaluation by subcutaneous delivery.
• Collaborate with public-health partners worldwide for TNX-801 clinical evaluation.
• Await a decision on marketing authorization for TNX-102 SL for fibromyalgia by the PDUFA goal date of August 15, 2025.

Key Dates

Recommendation

Keywords

Tonix Pharmaceuticals, TNX-801, vaccine, mpox, smallpox, horsepox, orthopox, preclinical data, attenuated, immunogenicity, subcutaneous administration, biopharmaceutical, infectious disease, TNX-102 SL, fibromyalgia, PDUFA, clinical development, public health